Tags

Type your tag names separated by a space and hit enter

Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine.
Headache. 2008 Sep; 48(8):1194-201.H

Abstract

OBJECTIVE

To examine the efficacy of rizatriptan for the treatment of pure menstrual migraine (PMM).

BACKGROUND

In 2004, the International Headache Society proposed new research criteria for menstrual migraine (International Classification of Headache Disorders [ICHD-II]). Two subtypes were defined: PMM, in which attacks occur exclusively with menstruation, and menstrually related migraine (MRM), in which attacks may also occur at other times of the cycle.

METHODS

The 2 protocols (MM1 and MM2) were identical randomized, double-blind studies. Adult patients with ICHD-II menstrual migraine were assigned to either rizatriptan 10-mg tablet or placebo (2:1). Patients were to treat a single menstrual migraine attack of moderate or severe pain intensity. This prospectively planned substudy pooled data from patients with a diagnosis of PMM from both studies. The primary substudy endpoint was 2-hour pain relief. Efficacy data were summarized for patients with a diagnosis of MRM.

RESULTS

Of 707 (MM1: 357, MM2: 350) patients treated in the study, 146 patients (MM1: 81, MM2: 65) had a diagnosis of PMM. The percentage of patients reporting 2-hour pain relief was significantly greater for rizatriptan than for placebo for both PMM (73% vs 50%, P = .006) and MRM subgroups (71% vs 52%, P < .001). Most other efficacy endpoints favored rizatriptan compared with placebo in patients with either PMM or MRM.

CONCLUSION

Rizatriptan 10 mg was superior to placebo for the treatment of PMM, as measured by 2-hour pain relief. Rizatriptan was also effective for the treatment of MRM and for relief of migraine-associated symptoms for both headache subtypes.

Authors+Show Affiliations

Texas Headache Associates, San Antonio, TX 78258, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18422606

Citation

Nett, Robert, et al. "Rizatriptan Efficacy in ICHD-II Pure Menstrual Migraine and Menstrually Related Migraine." Headache, vol. 48, no. 8, 2008, pp. 1194-201.
Nett R, Mannix LK, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache. 2008;48(8):1194-201.
Nett, R., Mannix, L. K., Mueller, L., Rodgers, A., Hustad, C. M., Skobieranda, F., & Ramsey, K. E. (2008). Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache, 48(8), 1194-201. https://doi.org/10.1111/j.1526-4610.2008.01093.x
Nett R, et al. Rizatriptan Efficacy in ICHD-II Pure Menstrual Migraine and Menstrually Related Migraine. Headache. 2008;48(8):1194-201. PubMed PMID: 18422606.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. AU - Nett,Robert, AU - Mannix,Lisa K, AU - Mueller,Loretta, AU - Rodgers,Anthony, AU - Hustad,Carolyn M, AU - Skobieranda,Franck, AU - Ramsey,Karen E, Y1 - 2008/04/14/ PY - 2008/4/22/pubmed PY - 2009/4/9/medline PY - 2008/4/22/entrez SP - 1194 EP - 201 JF - Headache JO - Headache VL - 48 IS - 8 N2 - OBJECTIVE: To examine the efficacy of rizatriptan for the treatment of pure menstrual migraine (PMM). BACKGROUND: In 2004, the International Headache Society proposed new research criteria for menstrual migraine (International Classification of Headache Disorders [ICHD-II]). Two subtypes were defined: PMM, in which attacks occur exclusively with menstruation, and menstrually related migraine (MRM), in which attacks may also occur at other times of the cycle. METHODS: The 2 protocols (MM1 and MM2) were identical randomized, double-blind studies. Adult patients with ICHD-II menstrual migraine were assigned to either rizatriptan 10-mg tablet or placebo (2:1). Patients were to treat a single menstrual migraine attack of moderate or severe pain intensity. This prospectively planned substudy pooled data from patients with a diagnosis of PMM from both studies. The primary substudy endpoint was 2-hour pain relief. Efficacy data were summarized for patients with a diagnosis of MRM. RESULTS: Of 707 (MM1: 357, MM2: 350) patients treated in the study, 146 patients (MM1: 81, MM2: 65) had a diagnosis of PMM. The percentage of patients reporting 2-hour pain relief was significantly greater for rizatriptan than for placebo for both PMM (73% vs 50%, P = .006) and MRM subgroups (71% vs 52%, P < .001). Most other efficacy endpoints favored rizatriptan compared with placebo in patients with either PMM or MRM. CONCLUSION: Rizatriptan 10 mg was superior to placebo for the treatment of PMM, as measured by 2-hour pain relief. Rizatriptan was also effective for the treatment of MRM and for relief of migraine-associated symptoms for both headache subtypes. SN - 1526-4610 UR - https://www.unboundmedicine.com/medline/citation/18422606/Rizatriptan_efficacy_in_ICHD_II_pure_menstrual_migraine_and_menstrually_related_migraine_ DB - PRIME DP - Unbound Medicine ER -